Latest oppositions filed by Modernatx, Inc.

This table presents recent patent oppositions filed by Modernatx, Inc. against its competitors. It outlines key details of each case, including the patent title, filing date and the applicant. This information provides insights into the competitive landscape and highlights active disputes over patent grant within the industry.

Patent NumberTitleApplicantOpposition Date
EP2958588Combination Of Vaccination And Inhibition Of The Pd-1 PathwayCUREVAC AGMay 22, 2018
EP2279254Novel Lipid Formulations For Nucleic Acid DeliveryARBUTUS BIOPHARMA CORPORATIONApr 5, 2018

The following table provides an overview of the latest patents of Modernatx, Inc. that has been opposed by its competitors. It provides an insight into the competitive landscape of the industry and highlights the patents that are subject to oppositions.

Patent NumberGrant DateTitleTotal Oppositions
EP3431485Sep 4, 2024Engineered Nucleic Acids And Methods Of Use Thereof2
EP3359670Feb 14, 2024Methods For Therapeutic Administration Of Messenger Ribonucleic Acid Drugs1
EP3578652Jul 12, 2023Ribonucleic Acid Purification1
EP3625345May 24, 2023Modified Messenger Rna Comprising Functional Rna Elements2
EP3458083Nov 2, 2022Polynucleotides Encoding Interleukin-12 (Il12) And Uses Thereof2
EP3324979Oct 12, 2022Infectious Disease Vaccines1
EP3590949May 18, 2022Ribonucleic Acids Containing N1-Methyl-Pseudouracils And Uses Thereof9
EP3718565Apr 27, 2022Respiratory Virus Vaccines4
EP2791160Mar 2, 2022Modified Nucleoside, Nucleotide, And Nucleic Acid Compositions10
EP2922554Feb 23, 2022Terminally Modified Rna1